Mirna Ruiz-Ramos

Las demencias son un conjunto de enfermedades neurodegenerativas, crónicas y progresivas, que se caracterizan por una disminución de las funciones cognitivas a un nivel que se pierde la autonomía y la independencia. Estas no tienen cura y el tratamiento se enfoca en mantener el mayor tiempo posible la funcionalidad de la persona. El manejo de estas enfermedades debe ser multidisciplinario y abarcar tanto las terapias farmacológicas como las no farmacológicas. El tratamiento de la DM2 incluye la indicación de hipoglucemiantes para disminuir la concentración sanguínea de glucosa a niveles normales. El efecto de los hipoglucemiantes convencionales sobre las funciones cognitivas es controversial, lo que justifica la continuidad en esta línea de investigación incluyendo su uso con coadyuvantes. En este contexto, se han realizado diversos estudios con diferentes nutraceúticos, siendo el resveratrol (RV) uno de los que podrían funcionar como coadyuvantes en el tratamiento del DCL y la DM2 porque ayuda a lograr un buen control glucémico, disminuir el EO y la IC y aumenta la neurogénesis.

Type 2 diabetes (T2D) affects a large part of the adult population and impairs its quality of life. Because of this, natural compounds with antioxidant, anti-inflammatory and hypoglycemic properties have been used as adjuvants. Among these compounds, resveratrol (RV) stands out, a polyphenol that has been studied in several clinical trials, the results of which are controversial. We conducted a randomized clinical trial on 97 older adults with T2D to evaluate the effect of RV on oxidative stress markers and sirtuin 1, using doses of 1000 mg/day (EG1000, n = 37) and 500 mg/day (EG500, n = 32) compared with a placebo (PG, n = 28). Biochemical markers, oxidative stress and sirtuin 1 levels were measured at baseline and after six months. We observed a statistically significant increase (p < 0.05) in total antioxidant capacity, antioxidant gap, the percentage of subjects without oxidant stress and sirtuin 1 levels in EG1000. In the PG, we observed a significant increase (p < 0.05) in lipoperoxides, isoprostanes and C-reactive protein levels. An increase in the oxidative stress score and in the percentage of subjects with mild and moderate oxidative stress was observed too. Our findings suggest that 1000 mg/day of RV exerts a more efficient antioxidant effect than 500 mg/day.

Background: Several clinical trials have suggested that resveratrol has hypoglycemic properties; however, there are other studies in which such an effect has not been observed. Methods: We carried out a systematic search in several databases; seventeen studies were selected for the systematic review and fifteen were included in the meta-analysis. Results: Resveratrol decreases glucose levels in subjects aged 45–59 years at doses p < 0.00001), 250–500 mg/day (−22.24 mg/dL, p = 0.0003), and 500–1000 mg/day (−28.40 mg/dL, p = 0.0008), while in subjects older than 60 years, it only decreases with doses of 250–500 mg/day. Likewise, HbA1c improved in subjects aged 45–59 years with doses of 250–500 mg (−0.60%, p < 0.00001), but not in subjects older than 60 years. Insulin levels improved in subjects aged 45–59 years with doses < 250 mg/day (−0.80 mIU/L, p = 0.0003) and doses of 250–500 mg/day (−5.0 mIU/L, p = 0.0003), although in subjects older than 60 years, they only improved with doses of 250–500 mg/day (−1.79 mIU/L, p = 0.01). On the other hand, HOMA-IR only improved in subjects older than 60 years with doses of 250–500 mg/day (−0.40, p = 0.01). Conclusions: Resveratrol has a statistically significant dose–response effect on glucose concentrations, HbA1c, and insulin levels; however, there is not enough scientific evidence to propose a therapeutic dose.

Caloric restriction (CR) has been shown to be an effective nutritional intervention for increasing longevity in some animal species. The objective of this study was to evaluate CR’s effects on metabolic and reproductive parameters in 12-month-old male Wistar rats. The rats were distributed in three groups: control, CR at 15%, and CR at 35% for 6 (up to 18 months of age) and 12 months (up to 24 months of age). At the end of CR treatment, we evaluated reproductive (male sexual behavior (MSB), sperm quality) and biochemical parameters (plasma glucose, glucose-regulating hormone, and sex steroid levels), and quantified annexin V in the seminiferous epithelium. Results showed that MSB and sperm quality were improved after 6 months of CR associated with increases in plasma testosterone and decrease annexin V in the seminiferous epithelium of the testicles compared to their control group. The metabolic profile of the CR rats also improved compared to controls. However, these effects of CR on reproductive parameters were not maintained after 12 months of CR. Findings suggest that beginning CR at the age of maturity reestablishes the behavioral sexual response and reproductive function in older animals after 6 months of CR and improves endocrine functioning during aging.

Background: Tagetes lucida Cav (T. lucida) is an herbaceous plant from the family Asteraceae, native to Mexico, Guatemala, and other Mesoamerican countries. Their common names are: (i) Spanish names: “hierbanís”, “jericón”, “pericón vomol”, “Santa María”, “cuchrucumín”, “falso hipericón”, “hierba añil”, “pericón”, “periquillo”; (ii) indigenous names: “ichka”, “cuahuyauhtli”, “yahuhtli”, “naná uarhi”, and (iii) English names: “sweet-scented marigold”, “sweet mace”, and “sweet marigold”., Its chemical composition of coumarins, estragole, quercetin, and flavonoids has antioxidant, anti-inflammatory, and antimicrobial effects. This study aimed to evaluate the effect of a mouthwash made with T. lucida for control of chronic periodontitis (CP) in older adults. Methods: We carried out a quasi-experimental study with a convenience sample of 60 older adults with CP. The sample was divided into a placebo group (PG) n = 30, administered with a mouthwash made with alcohol diluted with purified water (10%), and the experimental group (EG) n = 30 treated with a mouthwash made with T. lucida extract in 10% alcohol; both groups were administered three times a day for three months. Results: We found a significant improvement in the EG group compared with the PG group in: probing pocket depth (baseline, 5.2 ± 0.81 vs. post-treatment, 3.1 ± 0.43, p < 0.05), the clinical attachment loss (baseline, 6.6 ± 1.9 vs. post-treatment, 2.1 ± 1.5, p < 0.05), lipoperoxides (baseline, 0.056 ± 0.03 vs. post-treatment, 0.034 ± 0.02 µmol/L, p < 0.05), and chronic inflammation markers (IL-1, IL-8, and TNF-α) (p < 0.05). Conclusions: Our findings suggest that mouthwash made with T. lucida extract, administered three times a day, clinically improved chronic periodontitis in older adults, associated to a significant decrease in lipoperoxides and proinflammatory markers.

Resveratrol (RV) is a polyphenolic compound with antioxidant, anti-inflammatory, and hypoglycemic properties. Several in vitro and animal model studies have demonstrated the beneficial effects of RV; however, the results in humans are not conclusive. After a search of different databases, 32 studies were selected for this systematic review and 30 were included in the meta-analysis. Studies that evaluated the effect of RV on glucose, insulin, HbA1c, and insulin resistance (HOMA-IR) levels were included. A significant decrease of glucose (−5.24 mg/dL, p = 0.002) and insulin levels (−1.23 mIU/L, p = 0.0003) was observed. HbA1c and HOMA-IR did not show significant changes. Due to heterogeneity, sub-analyzes were performed. Sub-analysis by dose revealed that glucose levels improve significantly after the administration of 500–1000 mg/day of RV (−7.54 mg/dL, p = 0.002), while insulin improves with doses lower than 500 mg/day (−1.43 mIU/L, p = 0.01) and greater than 1000 mg/day (−2.12 mIU/L, p = 0.03). HbA1c and HOMA-IR remained unchanged after sub-analysis by dose. Our findings suggest that RV improves glucose and insulin levels in subjects with type 2 diabetes mellitus (T2DM) and aged 45–59 years, regardless of the duration of the intervention. HbA1c improves with interventions ≥3 months. HOMA-IR does not exhibit significant changes after RV administration.

It has been shown that health programs are useful for the prevention and control of chronic diseases in community-dwelling older people; however, a negative self-perception of old age could have an effect on the results. Therefore, our aim was to evaluate the effect of a healthy aging program linked to self-perception of old age in Mexican community-dwelling older people. A pre-test/post-test single-group design study was conducted in a convenience sample of 64 older people who undertook the entire healthy aging program workshop (five months’ duration). We measured self-perception of old age, efficacy of self-care, blood glucose concentration, anthropometric measures, and blood pressure before and after the workshop. A statistically significant decrease in blood glucose concentration was observed (baseline 136 ± 50 vs. post-intervention, 124 ± 45 ± 29 mg/dL, p < 0.01), LDL (baseline 153 ± 47 vs. post-intervention, 130 ± 36 mg/dL, p < 0.01), systolic blood pressure (130 ± 20 vs. 119 ± 11 mm/Hg, p < 0.001), and diastolic blood pressure (75 ± 9 vs. 72 ± 7 mm/Hg, p < 0.05) after community intervention. However, when we analyzed the data regarding self-perception, we found that this difference was only maintained in the subgroup of older adults with a positive self-perception of old age. Our findings suggest that the self-perception of old age influences the effect of healthy aging programs on the health of community-dwelling older people.